top of page

Publications

Original Article

A plasma protein derived TGFβ signature is a prognostic indicator in triple negative breast cancer

General Immune Research

2019

Authors:

Katayama H, Tsou P, Kobayashi M, Capello M, Wang H, Esteva F, Disis ML, Hanash S.

Journal:

NPJ Precision Oncology

Volume:

3

Page:

10

Review Article

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

2019

Authors:

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

Journal:

Journal of Immunotherapy Cancer

Volume:

7(1)

Page:

131

Review Article

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

General Immune Research

2019

Authors:

Page DB, Bear H, Prabhakaran S, Gatti-Mays ME, Thomas A, Cobain E, McArthur H, Balko JM, Gameiro SR, Nanda R, Gulley JL, Kalinsky K, White J, Litton J, Chmura SJ, Polley MY, Vincent B, Cescon DW, Disis ML, Sparano JA, Mittendorf EA, Adams S.

Journal:

NPJ Breast Cancer

Volume:

5

Page:

34

Review Article

Crafting a JAMA Oncology Clinical Challenge

2019

Authors:

Morrow M, Disis ML.

Journal:

JAMA Oncology

Volume:

Page:

Review Article

Immuno-Oncology in the Era of Personalized Medicine

2019

Authors:

Gwin WR 3rd, Disis ML, Ruiz-Garcia E.

Journal:

Advances of Experimental Medicine and Biology

Volume:

1168

Page:

117-129

Review Article

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

2019

Authors:

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

Journal:

Journal of Immunotherapy Cancer

Volume:

7(1)

Page:

167

Review Article

Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

2019

Authors:

Pal SK, Miller MJ, Agarwal N, Chang SM, Chavez-MacGregor M, Cohen E, Cole S, Dale W, Magid Diefenbach CS, Disis ML, Dreicer R, Graham DL, Henry NL, Jones J, Keedy V, Klepin HD, Markham MJ, Mittendorf EA, Rodriguez-Galindo C, Sabel MS, Schilsky RL, Sznol M, Tap WD, Westin SN, Johnson BE.

Journal:

Journal of Clinical Oncology

Volume:

37(10)

Page:

834-849

Original Article

Tumor-associated antigens identified early in mouse mammary tumor development can be effective vaccine targets

Cancer Vaccines

2019

Authors:

Stanton SE, Gad E, Corulli LR, Lu H, Disis ML.

Journal:

Vaccine

Volume:

37(27)

Page:

3552-3561

Review Article

Current Landscape of Immunotherapy in Breast Cancer: A Review

2019

Authors:

Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L, Bear H, McArthur HL, Frank E, Perlmutter J, Page DB, Vincent B, Hayes JF, Gulley JL, Litton JK, Hortobagyi GN, Chia S, Krop I, White J, Sparano J, Disis ML, Mittendorf EA.

Journal:

JAMA Oncology

Volume:

5(8)

Page:

1205-1214

Original Article

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial

Clinical Trials

2019

Authors:

Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, Chand V, Gulley JL.

Journal:

Jama Oncology

Volume:

5(3)

Page:

393-401

bottom of page